Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Citius Pharmaceuticals Inc is a biotechnology business based in the US. Citius Pharmaceuticals shares (CTXR) are listed on the NASDAQ and all prices are listed in US Dollars. Citius Pharmaceuticals employs 15 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.98 |
|---|---|
| 52-week range | $0.83 - $3.85 |
| 50-day moving average | $1.03 |
| 200-day moving average | $1.56 |
| Wall St. target price | $6.67 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.20 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.977 from 2022-06-24
| 1 week (2022-06-17) | 10.88% |
|---|---|
| 1 month (2022-05-23) | N/A |
| 3 months (2022-03-24) | -48.31% |
| 6 months (2021-12-23) | N/A |
| 1 year (2021-06-25) | -74.42% |
|---|---|
| 2 years (2020-06-26) | -29.20% |
| 3 years (2019-06-27) | 4.92% |
| 5 years (2017-06-26) | 6.22 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -13.35% |
| Return on equity TTM | -22.6% |
| Profit margin | 0% |
| Book value | $0.81 |
| Market capitalisation | $142.7 million |
TTM: trailing 12 months
We're not expecting Citius Pharmaceuticals to pay a dividend over the next 12 months.
Citius Pharmaceuticals's shares were split on a 1:15 basis on 8 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Citius Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Citius Pharmaceuticals shares which in turn could have impacted Citius Pharmaceuticals's share price.
Over the last 12 months, Citius Pharmaceuticals's shares have ranged in value from as little as $0.831 up to $3.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Citius Pharmaceuticals's is 1.6484. This would suggest that Citius Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Citius Pharmaceuticals, Inc. , a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. .
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Everything we know about the NYIAX IPO, plus information on how to buy in.
Everything we know about the Adamas One Corp IPO, plus information on how to buy in.
Everything we know about the Glucose Health IPO, plus information on how to buy in.
Everything we know about the Boustead Wavefront IPO, plus information on how to buy in.
Everything we know about the ParaZero Technologies IPO, plus information on how to buy in.